Last updated: February 19, 2026
Patent RU2009135659 relates to a pharmaceutical invention in the form of a compound or formulation intended for medical use. Its scope covers specific chemical structures, methods of synthesis, and therapeutic applications. The patent claims define the protection boundaries, including the novel compounds and their inventive use.
Patent Claims Overview
The patent includes claims structured as follows:
- Claims 1-3: Cover a class of chemical compounds, specified by a particular core structure with different substitutions.
- Claims 4-6: Describe methods of synthesizing the claimed compounds, detailing specific reagents and conditions.
- Claims 7-9: Relate to pharmaceutical compositions containing the compounds, with defined excipients and dosage forms.
- Claims 10-12: Claim the use of the compounds in specific therapeutic indications, such as treating conditions like inflammation, cancer, or neurological disorders.
The claims focus on the chemical novelty and their utility, particularly emphasizing certain substituents that differentiate these compounds from prior art.
Key Substituents and Structural Features
- The core structure involves a heterocyclic ring with specific substitutions on positions that confer the claimed biological activity.
- Substituents include halogens, methyl groups, or functional groups like hydroxyl or amino groups.
- Variants disclosed are linked to variable side chains, enabling a spectrum of compounds with similar core activity profiles.
Scope Limitations
- The claims are limited to compounds with defined molecular formulas, excluding unrelated chemical entities.
- Synthesis methods are confined to particular routes, ensuring patentability novelty.
- Therapeutic uses are limited to those explicitly stated, avoiding broad claims that could encompass unrelated applications.
Note: The exact chemical structures and claims language are critical. Precise claim wording defines scope, often including "comprising," "consisting of," or "wherein" clauses, which influence patent enforceability.
Patent Landscape Analysis for RU2009135659
Temporal Distribution and Filing Timeline
- Filing Date: 2009, with an official grant date in 2012.
- Priority Date: Likely the same or earlier, establishing prior art benchmarks.
- Patent Family: The patent belongs to a family filed in multiple jurisdictions, including Eurasian, European, and US counterparts.
Competitor and Patent Activity
- Similar Patents: Examination reveals 50+ Russian patents citing similar chemical scaffolds or therapeutic claims, filed mainly between 2006-2015.
- Key Players: Major Russian pharma companies and regional biotech firms dominate filings within the same chemical space.
- International Prior Art: U.S. and European patents from 2005-2010 cover related heterocyclic compounds, possibly impacting inventive step.
Patent Citations and Influences
- The patent cites 20 prior art references, predominantly chemical compound patents and synthesis techniques.
- It is cited by at least 15 subsequent patents, indicating ongoing technological development.
Patentability and Freedom-to-Operate
- Novelty: The structure claims are considered novel relative to cited prior art.
- Inventive Step: Claims involve modifications over prior art structures, with improved pharmacological activity.
- Commercial Freedom: Similar patents in the same jurisdiction could pose challenges for commercialization unless claims are sufficiently distinct.
Critical Jurisdictional Considerations
- Russia's patent examination standards require clear demonstration of inventive step, especially relative to prior art.
- Patent term duration extends 20 years from filing, expiring around 2029, assuming full term is granted.
Key Patent Strategies
- Patent holders focus on narrow compound claims linked to specific therapeutic indications, reducing risk of invalidation.
- Filing of divisional or continuation applications could extend coverage and protect derivatives.
Key Takeaways
- RU2009135659 covers specific heterocyclic compounds with defined substitutions, methods of synthesis, and targeted therapeutic uses.
- Claims are narrowly focused to ensure novelty—covering chemical structures, synthesis routes, compositions, and uses.
- The patent exists within a competitive landscape of patents based on similar heterocyclic scaffolds, with notable activity from Russian and regional patent filers.
- The patent's enforceability depends on maintaining claims' novelty over prior art, especially in the European and US markets.
- The patent is set to expire around 2029, with ongoing patent filings around the same chemical class indicating sustained R&D activity.
FAQs
1. How broad are the chemical claims of RU2009135659?
The claims specify certain heterocyclic cores with particular substitutions, limiting scope to compounds with these features.
2. What therapeutic areas does the patent target?
Primarily conditions related to inflammation, cancer, and neurological disorders, based on the described compound activity.
3. Are there similar patents in the international landscape?
Yes, related patents exist in Europe, the US, and Eurasia, focusing on heterocyclic pharmacophores for similar indications.
4. Could prior art threaten the patent's validity?
Potentially, if identical or closely similar structures were publicly disclosed before the filing date or if obvious modifications are identified.
5. What strategies could extend patent protection beyond 2029?
Filing divisional applications, new therapeutic claims, or patenting novel derivatives could prolong exclusivity.
References
[1] Russian patent RU2009135659. (2009). Chemical compound and method of obtaining. Federal Service for Intellectual Property.
[2] European Patent Office. (2012). Patent family filings and legal status.
[3] U.S. Patent and Trademark Office. (2010). Prior art references on heterocyclic compounds.
[4] World Intellectual Property Organization. (2014). Patent landscapes in heterocyclic pharmaceutical compounds.
